Male hypogonadism, also known as testosterone deficiency, is a failure of the testes to produce the male sex hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland.
This report contains market size and forecasts of Male Hypogonadism Therapy in Global, including the following market information:
Global Male Hypogonadism Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Male Hypogonadism Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Parenteral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Male Hypogonadism Therapy include Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Male Hypogonadism Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Male Hypogonadism Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Male Hypogonadism Therapy Market Segment Percentages, by Type, 2021 (%)
Parenteral
Transdermal
Oral
Others
Global Male Hypogonadism Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Male Hypogonadism Therapy Market Segment Percentages, by Application, 2021 (%)
Hospitals
Drugstores
Others
Global Male Hypogonadism Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Male Hypogonadism Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Male Hypogonadism Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Male Hypogonadism Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD